POMONA, Calif., June 27, 2024
/PRNewswire/ -- Amsino Medical Group ("Amsino"), a global provider
of medical consumable devices, is pleased to announce the closing
of a substantial investment by Novo Tellus, a leading investment
firm specialising in long-term investments in the global supply
chain.
Novo Tellus is deeply familiar with Amsino, having previously
partnered with Amsino to create substantial growth between 2011 and
2017. Amsino's management team and Novo Tellus aim to work closely
again to grow Amsino's global production, R&D, and commitment
to quality to deliver better and better solutions to customers
around the world.
"We're excited to renew a long-term partnership with Novo
Tellus" said Dr. Richard Y. Lee,
Chairman and CEO of Amsino Medical Group, noting that "Novo Tellus
has proven itself as a growth partner for Amsino before, and shares
our fundamental commitment to delivering dependable innovation and
value to our customers around the world."
"We are already working with Novo Tellus to build Amsino into a
next-generation global medical supplier. We're expanding our
production facilities in the US and growing our supply chain to
deliver more solutions, closer to market, for our customers. We're
proud of the long-term relationships we have with healthcare
customers around the world, and we're investing in research and
advanced manufacturing to bring better and better solutions to
market over time," added Dr. Lee.
Novo Tellus Managing Partner Loke Wai San said, "we've been
long-term believers in Amsino's approach of delivering critical
medical consumables to valued customers around the world. Today, as
the global supply chain shifts in response to economic and
geopolitical changes, we've listened to the market, and we see
great strategic opportunity with growing Amsino's existing US
production to serve more customers more deeply here in the domestic
market."
Reflecting on Amsino's global prospects, Robert Chen (Operating Partner) and Pei Shan Wong (Senior Vice President) at Novo
Tellus noted that "Amsino has always been a global company, and
even as we grow our US operations in support of our US customers,
we're looking to expand Amsino's global footprint and operations.
The global supply chain now demands more of suppliers: more
products, more manufacturing locations, greater availability, and a
shorter supply chain. With its US headquarters, established branded
offerings, and deep experience in US and Asia operations, Amsino is strategically
positioned to grow into a leading supplier of diversified medical
consumables worldwide."
The investment was made with all equity and no debt from Novo
Tellus investment funds, and closed in June
2024, with Novo Tellus and Amsino already working actively
to build the Company's future together.
About Amsino Medical Group
Amsino Medical Group, headquartered in Pomona, USA, is renowned for its comprehensive
portfolio of medical devices, including urological, infusion
therapy, and patient care products. With a strong emphasis on
quality and innovation, Amsino has established itself as a trusted
partner for healthcare providers worldwide. To learn more about
partnering with Amsino, visit amsino.com.
About Novo Tellus
Novo Tellus is a private equity firm focused on building lasting
technology and industrial companies in Southeast Asia. The firm is distinguished by
its deep insight into shifts in the global technology ecosystem,
and by its active and empathic partnerships with management teams
to build lasting businesses and superior investment returns. To
learn more about partnering with Novo Tellus, visit
novotellus.com.
Photo -
https://mma.prnewswire.com/media/2448658/Amulet_NT_closing_press_release_240626__Final___002.jpg
Logo - https://mma.prnewswire.com/media/2448657/amsino_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/amsino-medical-group-announces-transformational-investment-from-novo-tellus-302184066.html